Literature DB >> 17560435

Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate.

Theo Nicholaou, Rachel Wong, Ian D Davis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560435     DOI: 10.1016/S0140-6736(07)60903-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  12 in total

1.  Pazopanib-related tumor lysis syndrome in metastatic clear cell renal cell carcinoma: a case report.

Authors:  Michael W van Kalleveen; Maudy Walraven; Mathijs P Hendriks
Journal:  Invest New Drugs       Date:  2018-02-20       Impact factor: 3.850

Review 2.  The double faced role of xanthine oxidoreductase in cancer.

Authors:  Man-Man Chen; Ling-Hua Meng
Journal:  Acta Pharmacol Sin       Date:  2021-11-22       Impact factor: 7.169

3.  Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.

Authors:  Anita Schwandt; Laura S Wood; Brian Rini; Robert Dreicer
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

4.  Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice.

Authors:  Adeline Yl Lim; Ignacio Segarra; Srikumar Chakravarthi; Sufyan Akram; John P Judson
Journal:  BMC Pharmacol       Date:  2010-10-15

5.  Potential protective effect of sunitinib after administration of diclofenac: biochemical and histopathological drug-drug interaction assessment in a mouse model.

Authors:  Jian Ren Tan; Srikumar Chakravarthi; John Paul Judson; Nagaraja Haleagrahara; Ignacio Segarra
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-05       Impact factor: 3.000

6.  Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.

Authors:  Judith Michels; Nathalie Lassau; Marine Gross-Goupil; Christophe Massard; Arnaud Mejean; Bernard Escudier
Journal:  Invest New Drugs       Date:  2009-06-24       Impact factor: 3.850

7.  An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review.

Authors:  Danica Maria Vodopivec; Jose Enrique Rubio; Alessia Fornoni; Oliver Lenz
Journal:  Case Rep Med       Date:  2012-05-27

8.  Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations.

Authors:  Hiroshi Miyata; Tappei Takada; Yu Toyoda; Hirotaka Matsuo; Kimiyoshi Ichida; Hiroshi Suzuki
Journal:  Front Pharmacol       Date:  2016-12-27       Impact factor: 5.810

9.  Trial watch: Immunostimulatory cytokines in cancer therapy.

Authors:  Erika Vacchelli; Fernando Aranda; Florine Obrist; Alexander Eggermont; Jérôme Galon; Isabelle Cremer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-06-03       Impact factor: 8.110

Review 10.  Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the Literature.

Authors:  Aibek E Mirrakhimov; Alaa M Ali; Maliha Khan; Aram Barbaryan
Journal:  Rare Tumors       Date:  2014-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.